Szarkóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• EGFR 1
• JAK 1
• PARP 4
• YAP 0
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• CXCR4 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• FLT3 0
• FTO 0
• HDAC 0

1920 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• FDA · U01

  Disulfiram/Copper as a Dual Senolytic Strategy Targeting Tumor and Immune Cell Senescence in Chordoma

  Massachusetts General Hospital· Boston, Egyesült Államok· 1 000 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, Egyesült Államok· 785 081 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, Egyesült Államok· 350 188 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAMS · R21

  Failure to resolve an adaptive stress state contributes to Duchenne Muscular Dystrophy Severity

  University of Southern California· Los Angeles, Egyesült Államok· 211 650 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

  Biologica Llc· Charlotte, Egyesült Államok· 385 056 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 2 302 626 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spanyolország· EU contribution 194 075 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting single-cell ploidy from digital pathology images in pan-sarcoma (SImPloidy)

  University College London· London, Egyesült Királyság· EU contribution 276 188 EUR· until 2027. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-IA

  Sustainable 4D hydrogels functionalised with plant-based nanoparticles for bone regeneration in cancer patients (GreenNanoBone)

  The University of Liverpool· Liverpool, Egyesült Királyság· EU contribution 8 649 982 EUR· until 2029. máj.· 12 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 473 running projects, newest first. Listed amounts together: 249,7 M USD + 53,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Visszavonták

  BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas

  NCT07027423· University Health Network, Toronto· Frissítve: 2026. nov. 13.

  “Unable to finalize the Clinical Trial Agreement with the drug manufacturer BOLD Therapeutics.”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

  NCT04539366· National Cancer Institute (NCI)· Frissítve: 2026. nov. 12.

  “Other - review of safety data”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

  NCT05075993· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 10.

  “\<75% participation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

  NCT03116529· University of Maryland, Baltimore· Frissítve: 2026. nov. 5.

  “Limited Accrual”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  NCT01552434· M.D. Anderson Cancer Center· Frissítve: 2026. nov. 5.

  “\< 75 % participation”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

  NCT05691478· National Cancer Institute (NCI)· Frissítve: 2026. okt. 27.

  “Other - Extend the observation period for current patients”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO)

  NCT06712433· Adam Olson· Frissítve: 2026. okt. 26.

  “Per the PI, this study is not proceeding due to funding and insufficient support.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

  NCT06566092· Iovance Biotherapeutics, Inc.· Frissítve: 2026. okt. 16.

  “After reviewing the available safety and efficacy data to date, Iovance has made the decision to conclude all remaining participant visits.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Digital Art Therapy for Young Cancer Survivors

  NCT06789666· UNC Lineberger Comprehensive Cancer Center· Frissítve: 2026. okt. 15.

  “Funding unavailable”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

  NCT07052383· Tcelltech Inc.· Frissítve: 2026. okt. 14.

  “Data update in progress.”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

  NCT04458922· National Cancer Institute (NCI)· Forrás

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Forrás

• Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

  NCT03914612· National Cancer Institute (NCI)· Forrás

• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04320888· National Cancer Institute (NCI)· Forrás

• Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

  NCT04339738· National Cancer Institute (NCI)· Forrás

• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

  NCT04195555· National Cancer Institute (NCI)· Forrás

• Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial

  NCT05333458· National Cancer Institute (NCI)· Forrás

• Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

  NCT04595747· National Cancer Institute (NCI)· Forrás

• Pomalidomide Treatment in Patients With Kaposi Sarcoma

  NCT04577755· National Cancer Institute (NCI)· Forrás

• Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

  NCT02923778· National Cancer Institute (NCI)· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 153
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 198
• Machine Learning 29
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• (Immuno-)Histological Analysis of Ewing Sarcoma.

  Methods Mol Biol, 2027. jan.

• Molecular Approaches to Diagnosis in Ewing Sarcoma: Fluorescence In Situ Hybridization (FISH).

  Methods Mol Biol, 2027. jan.

• Ewing sarcoma of the spermatic cord - A rare extra-skeletal presentation.

  Indian J Pathol Microbiol, 2026. okt.

• A rare case of synchronous leiomyosarcoma in the jejunum and sigmoid colon.

  J Cancer Res Ther, 2026. okt.

• A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival.

  J Cancer Res Ther, 2026. okt.

• Utility of p53 immunohistochemistry in atypical fibroxanthoma and pleomorphic dermal sarcoma: a retrospective study of 50 patients.

  Clin Exp Dermatol, 2026. okt.

• Langerhans cell sarcoma in the central nervous system mimicking a meningioma: case report and literature review.

  Ultrastruct Pathol, 2026. okt.

• PD-L1 Expression in Uterine Mesenchymal Tumors: A Comparative Immunohistochemical Analysis.

  J Obstet Gynaecol Res, 2026. okt.

• Primary NTRK-rearranged spindle cell sarcoma of the colon with ETV6-NTRK3 fusion.

  BMJ Case Rep, 2026. szept.

• PRAME as a Diagnostic Adjunct in Clear Cell Sarcoma.

  Appl Immunohistochem Mol Morphol, 2026. szept.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.